Cardiology fellow @semmelweishu | Alumni research fellow @MassGeneral @CIRC_MGH | #CVImaging & #Cardiooncology
Budapest
Joined February 2012
- Tweets199
- Following904
- Followers431
- Likes1.4K
Zsofia D. Drobni, MD, PhD retweeted
Which Cardiac Troponin do You use in a patient with suspected ICI Myocarditis? Great to share @InovaHealth approach in #JACCCardioOnc @JACCJournals @ChrisDefilippi @RaymondWadlowMD @InovaSchar @ISHVnews sciencedirect.com/science/ar…
Zsofia D. Drobni, MD, PhD retweeted
Upgrade to cardiac resynchronisation therapy benefits #HeartFailure patients with pacing bit.ly/3quHgPG
#ESCCongress @DrMerkely
Zsofia D. Drobni, MD, PhD retweeted
Among study participants with lymphoma who were being treated with anthracyclines, prophylactic use of atorvastatin over 12 months was associated with a lower rate of cardiac systolic dysfunction. ja.ma/3QtDb8M
Zsofia D. Drobni, MD, PhD retweeted
Dr. Scott David Solomon, the world-renowned cardiologist of Harvard Medical School received the university’s most prestigious international scientific recognition, the Semmelweis Budapest Award. Heartfelt congratulations to Professor Solomon!
Read more:
semmelweis.hu/english/2023/0…
Zsofia D. Drobni, MD, PhD retweeted
New #JITC article: Impact of immune checkpoint inhibitors on atherosclerosis progression in patients with lung cancer bit.ly/3JU7gKE @zsofidrobni @TomasNeilan
Zsofia D. Drobni, MD, PhD retweeted
Should post STEMI PCI pathway include routine #FFRCT for assessing flow impairment of non culprit lesions? 🫀Thought provoking #XPECTMI study suggests #YesCCT at index event can predict future invasive FFR‼️
Fantastic work by @semmelweishu researchers! Congrats!
Zsofia D. Drobni, MD, PhD retweeted
Congrats @husam247 and @dineshpmcc1. Definitely enough now to think of a RCT. If only the SGLT2i companies were interested…
We are excited to share our latest open-access #cardiooncology paper examining the enticing idea that SGLT2I use during anthracycline chemotherapy with the risk of #heartfailure by reducing the risk of #cardiotoxicity
sciencedirect.com/science/ar…
Zsofia D. Drobni, MD, PhD retweeted
Fabulous work by @zsofidrobni from @semmelweishu and @CIRC_MGH on atherosclerosis with immune therapy. Thank you Dr. Ky for your leadership and your interest in this work. #ACC2023 #cardioonc
Zsofia D. Drobni, MD, PhD retweeted
Grateful for this amazing #CardioOnc team 🫀💉💊 with @zsofidrobni led by the @TomasNeilan @CIRC_MGH @MGHHeartHealth.
Zsofia D. Drobni, MD, PhD retweeted
Ibolya is a fantastic medical educator and recipient of @EinsteinMed Davidoff Society Teaching star award. 🌟
She is a team player, and an incredible source of support to her co-residents and interns. Thank you Ibi!! #JacobiStrong #MedTwitter #IMG #CardioTwitter
Zsofia D. Drobni, MD, PhD retweeted
From @jaccjournals, over 30% of cancer patients are eligible for an ICI. A review on the potential for ICI related atherosclerosis - JACC: CardioOncology led by the amazing @GiselleSA_MDPhD from @MGHHeartHealth and @MGHCVFellows rb.gy/sgywti
Zsofia D. Drobni, MD, PhD retweeted
Sodium-glucose cotransporter-2 inhibitors and heart failure and mortality in patients with cancer heart.bmj.com/content/early/…
In a large mostly non-anthracycline cancer population, SGLT2i use was associated with lower incident HF and prolonged overall survival
Zsofia D. Drobni, MD, PhD retweeted
Be sure to read the latest ESMO Clinical Practice Guideline @Annals_Oncology for multi-disciplinary guidance on toxicities from cancer immunotherapy. @myESMO
annalsofoncology.org/article…
Zsofia D. Drobni, MD, PhD retweeted
Excellent discussion case on 5-FU toxicity/capecitabine - by Dr Nohria, @b_dhesy - the case is not clear yet.. tune in to hear till the end of pre-conference of #GCOS22 @dineshpmcc1
Drs. Anju Nohria and Bindi Dhesy-Thind sharing their expertise about fluorouracil associated cardiotoxicity at the #gcos2022 pre-meeting #cardiooncology
Zsofia D. Drobni, MD, PhD retweeted
#GCOS2022 Pre-conference starting today - 1 PM EST. Listen to @JLiu_MSKCardOnc and @TeresaLpezFdez1 discuss 3D + strain acquisition and analysis - tips and tricks. Then highly interactive case discussions with experts! @ICOSociety @CCardiacON @trogersresearch @PMunkCardiacCtr
Zsofia D. Drobni, MD, PhD retweeted
Check out this practical guide how to quantify #YesCCT coronary atherosclerotic plaques ⬇️⬇️⬇️
Fantastic work by @Balint_CCTA @PalMaurovich @MKolossvary @MarcDweck 👏👏👏🇭🇺
@semmelweishu @zsofidrobni @KaradyJ
NEW practical guide in #EHJCVI:
💎 How to quantify coronary atherosclerotic plaque by #YesCCT
Find out the tips from #EACVI experts
@gpontone1 @MarcDweck @PalMaurovich
doi.org/10.1093/ehjci/jeac19…
@GeraldMaurer @ESC_Journals @escardio @EACVIPresident @s_e_petersen
Zsofia D. Drobni, MD, PhD retweeted
Something new for ESC...
Join us in “The Zone”
16:30 every day
Education / Guidelines
Entertainment / Resident DJ
Interactive quiz / Discussion
@Steph_Achenbach
@escardio
@Sarah_Moharem
@DrMarkWestwood1
@CardiacJoshi
@dromar_c
@vass_vassiliou
@MarkNicholls5 – at South East, England
Zsofia D. Drobni, MD, PhD retweeted
Late post: So grateful to receive this recognition @EinsteinMed for teaching!
Lucky to work with such talented and diverse group of students & residents and to be surrounded by nurturing leadership. @AndrewGutwein @jmcchiefs
Looking forward to the next rotation as PGY2 🏋️♀️
Zsofia D. Drobni, MD, PhD retweeted
SGLT2i and Cardiac Outcomes Among Patients Treated With Anthracyclines
This retrospective cohort study showed that the use of #SGLT2i in DM pts being treated with #anthracyclines is safe and associated with a lower cardiac event rate
jacc.org/doi/10.1016/j.jchf.… #JACCHF @JACCJournals
